# Junta clínica — PT-pseudo_d38917f87b35 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d38917f87b35",
  "pid": "PT-pseudo_d38917f87b35",
  "task": 1,
  "psa": 28.3,
  "age": 61,
  "months": 2,
  "pirads": "5",
  "psad": 0.4,
  "psav": -0.78,
  "psap": 25.3,
  "vol": 70.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.8709831,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia",
  "meds": "empagliflozin, simvastatin, rosuvastatin",
  "notes": "PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "99 kg",
    "height": "177 cm",
    "bmi": "31.6",
    "bp": "126/68 mmHg",
    "hr": "67 bpm",
    "smoking": "Ex-smoker (23 pack-yr, quit 2015)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review."
    },
    {
      "s": "History",
      "t": "A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable."
    }
  ],
  "occupation": "retired firefighter",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "12 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 19/35 (moderate LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d38917f87b35
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 28.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: -0.78 ng/mL/yr
  - Prior PSA: 25.3 ng/mL
  - Prostate volume: 70.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8709831 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia
  - Current medication: empagliflozin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.

Vitals: weight 99 kg, height 177 cm, BMI 31.6, BP 126/68 mmHg, HR 67 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2015).

Chief complaint: Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review.

History: A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable.

Patient info: retired firefighter; Widowed; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 12 units / week; exercise Running 3x/week, 5 km; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.25
  uncertainty  +/- 0.11 (95% CI 0.05-0.46); among patients it cannot tell apart the outcome was 0.82 of 1.00 mixed
  confidence   HIGH — in this tier it was right in every one of the 28 labelled cases it covered

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a repeat PSA test before prostate biopsies in men with an initial PSA of 3-10 ng/mL reduced the indication for biopsies in 16.8% of men. It also notes that a PSA change alone should not change management based on its weak link with grade progression.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's bid fails to account for the critical role of the PI-RADS score and the specific PSA density threshold that the guideline uses for risk stratification. It cannot weigh the risk-adapted matrix that links PI-RADS scores to PSA density categories, which is a variable the guideline makes decisive that the classifier could not read.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 5, which is a high-risk finding, which suggests a need for further investigation according to the guideline's risk-adapted matrix.
The PSA density - The PSA density is 0.4 ng/mL², which is above the guideline's suggested cut-off of 0.15 ng/mL/cc, which is a variable the guideline makes decisive that the classifier could not read.
The prior biopsy status - The prior biopsy status is 'Positive', which is a factor the guideline makes decisive that the classifier could not read.
The prostate volume - The prostate volume is 70.0 mL, which is a variable the guideline makes decisive that the classifier could not read.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on integrating the high PI-RADS score and the PSA density with the prior positive biopsy result to determine the next step.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, including lesion size, zone, and extraprostatic extension.
  previous_notes (get_previous_notes) -> Review the management context, specifically the prior biopsy result and any prior surveillance plans.
  psa_trend (get_psa_trend) -> What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period?

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose show regarding the lesion size, zone, and extraprostatic extension?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. psa_trend was added to the plan: the reading urologist opened it in 87% of the labelled cases, and it carries a fact this decision turns on. Dropped 1 question(s) that asked for a value already printed on the panel: "How does the PSA density of 0.4 ng/mL² relate to the guideline's risk-adapted matrix?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose shows a left peripheral zone mass measuring roughly 28 mm longest diameter, with marked diffusion restriction. It indicates a PI-RADS 5 score and an estimated csPCa probability of 0.8709831.

previous_notes
The management context shows a prior biopsy confirmed a Positive finding of ISUP GG5 disease. Previous notes document a rising PSA trend from 22.4 ng/mL in December 2023 to 28.3 ng/mL in January 2025.

psa_trend
The serial PSA has shown a rising trend from 1.3 ng/mL in July 2023 to 28.3 ng/mL in January 2025.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator stated that the DRE and headline PSA were already on the panel, and the specific questions for the lab were not required to answer the open questions.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose shows a PI-RADS 5 score, which suggests a need for further investigation according to the guideline's risk-adapted matrix.
The serial PSA has shown a rising trend from 1.3 ng/mL in July 2023 to 28.3 ng/mL in January 2025.

AGAINST sampling this patient now
The prior biopsy status is 'Positive', meaning the patient already has a tissue diagnosis.

WHERE THIS LEANS
The findings strongly suggest that the high-risk imaging features combined with the rising PSA warrant further action, despite the prior diagnosis.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, previous_notes, and psa_trend—have answered the moderator's question Q1 by providing the mpMRI prose, which shows a left peripheral zone mass measuring roughly 28 mm longest diameter, with marked diffusion restriction, a PI-RADS 5 score, and an estimated csPCa probability of 0.8709831.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of NO BIOPSY (p=0.25), as the Registrar's findings present conflicting signals: the high-risk imaging and rising PSA support biopsy, while the prior positive biopsy argues against it.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose show regarding the lesion size, zone, and extraprostatic extension? This is answered by the radiology_report, which shows a left peripheral zone mass measuring roughly 28 mm longest diameter with marked diffusion restriction and a PI-RADS 5 score.
Q2. Review the management context, specifically the prior biopsy result and any prior surveillance plans. This is answered by the previous_notes, which confirm a prior biopsy confirmed a Positive finding of ISUP GG5 disease.
Q3. What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period? This is answered by the psa_trend, which shows a rising trend from 1.3 ng/mL in July 2023 to 28.3 ng/mL in January 2025.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS score (5), which matters because it suggests a need for further investigation according to the guideline's risk-adapted matrix, and the rising PSA trend, which matters because it indicates progression. The prior biopsy status is a variable the guideline makes decisive that the room has been leaning on, as it suggests a definitive diagnosis already exists.

MY SUGGESTION TO THE CHAIR
Given the conflict between the high-risk imaging/rising PSA and the prior positive biopsy, the evidence is not sufficient to definitively decide based on the guideline's terms alone. The case is not in a state to be decided yet because the conflict requires further integration of the data.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: no closed document is left that could answer. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: borderline)

Although the mpMRI showed a high-risk PI-RADS 5 score and the PSA trend was rising, the prior biopsy confirmed a positive finding of ISUP GG5 disease, meaning the diagnosis is already characterized. The conflict between the high-risk imaging and the prior diagnosis prevents a definitive decision based on the retrieved data. Therefore, I defer biopsy as the existing tissue diagnosis is sufficient to guide management.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, previous_notes, psa_trend
